We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.
Researchers discovered the secret checkpoints that keep CRISPR precise, revealing how the tool shifts from inactive to active without misfiring. The insight could transform gene therapy, making ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when it reports first-quarter 2025 results. The Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results